Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

43.54
-0.4600-1.05%
Post-market: 43.610.0700+0.16%19:56 EDT
Volume:2.31M
Turnover:100.67M
Market Cap:7.24B
PE:-12.51
High:44.17
Open:44.17
Low:43.24
Close:44.00
52wk High:86.74
52wk Low:43.01
Shares:166.18M
Float Shares:161.92M
Volume Ratio:0.63
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:16.45
PE(LYR):-18.28

Loading ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: cbdMD (YCBD) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Sep 04

Ionis Pharmaceuticals' Zanvastro Approval Sets Path for Independent Neurology Business, Oppenheimer Says

MT Newswires Live
·
Sep 04

Ionis Pharmaceuticals Exec Says Zanvastro Will be Available at List Price of $285,000 Per Dose

THOMSON REUTERS
·
Sep 04

U.S. Stocks on the MOVE-Lululemon Athletica, Adobe, Ionis Pharmaceuticals

Reuters
·
Sep 04

Ionis Pharmaceuticals (IONS) Receives a Hold from BMO Capital

TIPRANKS
·
Sep 04

Ionis Pharmaceuticals Price Target Maintained with a $115.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 04

Ionis Pharma up After US FDA Approves Rare Brain Disorder Treatment

Reuters
·
Sep 04

Ionis Pharmaceuticals Gets FDA Approval for Alexander Disease Treatment

MT Newswires Live
·
Sep 04

U.S. Research Roundup-Ciena Corp, Docusign, Snowflake

Reuters
·
Sep 04

Ionis Pharmaceuticals, Inc. : Jefferies Cuts Target Price to $88 from $90

THOMSON REUTERS
·
Sep 04

US FDA Approves Ionis Pharma's Therapy to Treat Rare Genetic Disorder

Reuters
·
Sep 04

FDA: Approves Zanvastro (Zilganersen) Injection for Treatment of Alexander Disease in Pediatric and Adult Patients

THOMSON REUTERS
·
Sep 04

Movement Alert|Ionis Pharmaceuticals Falls 5.06% in Regular Trading, Trading at $58.215

Market Focus
·
Sep 04

Ultragenyx Hits Record Low After Rare Disease Drug Trial Failure

Reuters
·
Sep 03

Ionis to Join Wells Fargo, Morgan Stanley Healthcare Investor Conference Fireside Chats

Reuters
·
Sep 03

Trump Administration Announces Drug Pricing Deals with CSL, Astellas and Others

Reuters
·
Sep 01

Ionis Pharmaceuticals Price Target Maintained with a $115.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 31

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Aug 31

Jefferies sees neutral to negative read-through to Alnylam from AstraZeneca data

TIPRANKS
·
Aug 28

Alnylam, Ionis Fall as Heart-Drug Data Raise Doubts over Combination Treatment

Reuters
·
Aug 28